Across
- 3. Carries a black box warning for osteosarcoma
- 6. Lower efficacy than first-line agents, may be beneficial for breast cancer, and increases the risk for DVT/stroke
- 10. Monoclonal antibody that targets RANKL and prevents activating RANK which is important in activating the action of osteoclasts; thus reducing bone resorption and increasing bone strength (brand name)
- 11. Brand name bisphosphonate that has an IV and oral formulation
- 12. Scoring system that includes clinical risk factors and is used to determine if a patient should begin osteoporosis therapy
- 13. Stimulates estrogen receptors selectively in bone tissue leading to an increase in bone strength (brand name)
- 16. Abbreviation for potential complication in patients taking zoledronic acid
- 17. Important supplement to consider in osteoporotic patients
- 18. Rare adverse effect of bisphosphonates that affects the jaw
- 19. This form of calcium is better absorbed than carbonate
- 20. Twice yearly injection that can cause low calcium and muscle pain as adverse effects
Down
- 1. Brand name medication that has anabolic (bone-building) effects by stimulating osteoblasts
- 2. Class of medication that is most often used first-line for osteoporosis
- 4. Beneficial for osteoporosis but avoided due to the risk of cancer and blood clots
- 5. Scan that assesses bone mineral density
- 7. Potential toxicity associated with zoledronic acid
- 8. Opposes the action of parathyroid hormone and inhibits the activity of osteoclasts which results in an increase in bone strength
- 9. This medication inhibits osteoclasts; osteoclasts breakdown bone to help pull calcium into the bloodstream
- 14. A value of -2.5 or lower is indicative of osteoporosis with this assessment
- 15. Nasal spray that can help with osteoporosis and compression fracture pain